Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00081926
Recruitment Status : Completed
First Posted : April 29, 2004
Last Update Posted : November 23, 2009
Information provided by:

Brief Summary:

This study will evaluate the molecular response to high dose Gleevec in newly diagnosed patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase. This study will evaluate the ability of Gleevec to reduce the amount of abnormal protein that occurs in patients with CML.

Patients who are eligible to participate will be treated for 18 months. This trial will include male or female patients 18 years or older who are newly diagnosed (within 6 months) with CML.

Condition or disease Intervention/treatment Phase
Chronic Myelogenous Leukemia Drug: Gleevec Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 112 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : October 2003
Study Completion Date : March 2007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Participants must meet all of the following criteria:

  • Male or Female patients 18 years and older.
  • Patient with a diagnosis of chronic myelogenous leukemia in chronic phase
  • Within 6 months of initial diagnosis.
  • Received any treatment for CML for less than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.

Exclusion Criteria:

  • Late chronic phase, accelerated phase or blastic phase
  • Taking any other investigational agents within 28 days of starting the study
  • If sibling donors have been identified and where allogeneic bone marrow transplantation will be the first line treatment.
  • Another primary malignancy /cancer unless it is not considered clinically significant or does not require active intervention.
  • If patients have heart problems or complications
  • Pregnant or breast-feeding females
  • Severe and/or uncontrolled disease such as diabetes, chronic renal disease, etc.
  • Chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
  • Diagnosis of human immunodeficiency virus (HIV) infection.
  • Received any treatment for CML for longer than 1 month prior to study entry with the exception of hydroxyurea and/or anagrelide.
  • Patient previously received radiotherapy to greater than 25% of the bone marrow.
  • Patient had a major surgery within 4 weeks prior to study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00081926

Layout table for location information
United States, New Jersey
Novartis RIGHT Trial Hotline
East Hanover, New Jersey, United States
Sponsors and Collaborators
Novartis Pharmaceuticals

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00081926    
Other Study ID Numbers: CSTI571AUS177
First Posted: April 29, 2004    Key Record Dates
Last Update Posted: November 23, 2009
Last Verified: November 2009
Keywords provided by Novartis:
Chronic Myelogenous Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action